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Abstract Distant metastasis is a major cause of colorectal cancer–related death, but the
mechanism of tumour progression is not fully understood. There is growing evidence
of an interaction between tumour cells and platelets which may inﬂuence tumour
progression and metastasis formation. Quality and quantity of von Willebrand factor
may regulate the interaction between tumour cells and platelets. Our aim was to
measure the platelet count, von Willebrand factor antigen (VWF:Ag) levels and
ADAMTS13 activity in a large (n ¼ 232) cohort of colorectal cancer patients and to
examine their relationships with the stage of the disease and 5-year survival without
thrombotic complications using multivariable models. Signiﬁcantly higher platelet
counts (p ¼ 0.005), VWF:Ag levels (p ¼ 0.008) and decreased ADAMTS13 activity
(p ¼ 0.006) were observed in patients with metastatic disease. Results of the Kaplan–
Meier analysis showed that lower platelet counts (p < 0.0001), lower VWF:Ag
(p ¼ 0.0008) levels and higher ADAMTS13 activity (p < 0.0001) were associated
with better event-free survival. Finally, to investigate the association between overall
event-free survival and the three study variables, multivariate Cox proportional hazard
models were generated. All models were adjusted for age, gender and disease stage.
Platelet count, ADAMTS13 activity or VWF:Ag level were incorporated and all of these
variables turned out to be age-, gender- and stage-independent predictors of mortality
(all hazard ratio >1.7, p < 0.05). In summary, this is the ﬁrst observational study
reporting association between higher mortality or thrombotic complications and
increased platelet count, increased VWF:Ag levels and decreased ADAMTS13 activity
in colorectal cancer.
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Introduction
Colorectal cancer is one of the leading causes of mortality all
over theworld. Based on theWHOWorld Cancer Report 2014,
colorectal cancer is the third most prevalent cancer type in
men and the second in women. It is the third most common
causeof cancer-relatedmortality inmenand fourth inwomen.
The mortality decreased in the last decades due to colo-
rectal screening and therapeutic improvements,1 but in spite
of that the presence of distant metastasis is a major cause of
colorectal cancer–related death.2 The survival of patients
with metastatic colorectal cancer is even worse than the
localized form of the disease.3
It is important to ﬁnd new reliable markers that can
predict the prognosis of colorectal cancer patients.
The contribution of platelets in metastasis formation has
been known for a long time. First, it was observed in themid-
19th century that venous thromboembolism and superﬁcial
thrombophlebitis occur together with malignancy.4 There is
growing evidence of an interaction between tumour cells
and platelets, which promote tumour progression.5 On the
one hand, tumour cells can induce platelet activation; on the
other hand, platelets can also promote tumour growth and
metastasis formation with various mechanisms reviewed
recently.4 Multiple studies investigated the role of platelets
in several cancer types, such as ovarian,6 lung7,8 and color-
ectal cancer.9–13 Preoperative thrombocytosis was asso-
ciated with poor survival in surgically resected colorectal
cancer patients14 and was identiﬁed as independent pre-
dictor of survival.11,12 Paraneoplastic thrombocytosis was
shown to be associated with decreased median time to
disease progression in ovarian cancer patients.15
The interactionbetweentumourcells andplatelets couldbe
mediated by multiple factors,4,5 among which the von Wil-
lebrand factor (VWF) belongs to the most widely studied
group. This multimeric glycoprotein is expressed in and re-
leased from platelets and endothelial cells, and can bind to
platelet surface receptors facilitating the formation of the
platelet thrombus. In clinical studies, an increased plasma
level of VWFantigen (VWF:Ag)was observed invarious cancer
types such as ovarian, bladder, gastric and colon cancer, and
increased levels were associated with poor prognosis.16,17
Themost adhesive formof the VWF is the ultra-large VWF,
which is released from the endothelial cells. Under physio-
logical circumstances, it is cleaved by ADAMTS13 (a dis-
integrin and metalloproteinase with thrombospondin type-I
repeats 13) protease into the multimer form in a shear-
dependent manner.18 Signiﬁcantly decreased ADAMTS13
serum levels were found in patients with localized or dis-
seminated tumours compared to healthy individuals.19 In
another study, an increased amount of ultra-large VWF
multimers and decreased ADAMTS13 activity were observed
in blood samples of patients with malignancies.20,21
Only few studies were performed in connectionwith VWF:
Ag level and ADAMTS13 activity in tumours. In patients with
disseminatedmetastasis, a reducedplasma level ofADAMTS13
was measured with the presence of unusually large VWF
multimers.22 Similar to this observation, a lowermeanplasma
level of ADAMTS13 was found in disseminated malignancies
comparedwith the localized form. TheADAMTS13activityand
VWF:Ag level correlate inversely.19 Although the epidemiolo-
gical evidence supporting the potential association of in-
creased platelet count and VWF:Ag level, or decreased
ADAMTS13 activity with poor survival in cancer patients, is
accumulating, none of the large studies evaluated these factors
simultaneously in colorectal cancer patients. Therefore, our
aim was to measure the platelet count, VWF:Ag level and
ADAMTS13 activity and examine its association with the
presence of ultra-large VWF in a large (n ¼ 232) cohort of
colorectal cancer patients, and to examine their relationships
with the presence of metastatic disease and 5-year survival
without thrombotic complications using multivariable mod-
els. Because the higher prothrombotic risk is associated with
increased platelet count and VWF:Ag level, or decreased
ADAMTS13 activity, we also compared these parameters in
relation to the thrombotic complications during the disease.
Materials and Methods
Patients
A total of 232 patients diagnosed with colorectal cancer were
enrolled in the study between January 2011 and June 2013 in
the Oncology Department of the 3rd Department of Internal
Medicine, Semmelweis University. The study was approved by
the Medical Research Council Scientiﬁc and Research Commit-
tee and was performed at the 3rd Department of Internal
Medicine, Semmelweis University, based on a study protocol
approved by the highest Ethical Committee of Hungary. Pa-
tients’ consent was obtained consecutively after the conﬁrma-
tion of colorectal cancerwith any stage,whichwas basedon the
TNM staging system. Blood sampleswere taken after 6 hours of
fasting between 8 and 10 AM by antecubital venipuncture into
native, EDTA, or sodium citrate–anticoagulated tubes before
starting any anticancer therapy. The samples were aliquoted
and stored at 70°C for further analysis. Clinical data were
collected. Baseline demographics and clinical characteristics of
patients are summarized in►Table 1. Themean age of patients
was 68.5 years, with a male:female ratio of 138:94. After
diagnosis and adequate surgery, patients were treated and
followed up at the Oncology Department according to the stage
of their disease and to the relevant guidelines. Patients with
rectal cancer received radiochemotherapy before deﬁnitive
surgery from cT3 or Nþ disease. Twenty-two patients who
had irresectable and/or metastatic disease received upfront
primary systemic treatment without deﬁnitive surgery. The
data of thrombotic complications, which were deﬁned as
occurrence of deep vein thrombosis, pulmonary embolism,
arterial occlusionwith infarction and superﬁcial thrombophle-
bitis,23were collected from the disease onset until the last visit
(median follow-up: 42.36 months). Patients were followed up
for 5 years (median: 46.42months) in the same institution and
survival and thrombotic data were recorded and deﬁned as
events. Most of the patients died due to progressive malignant
disease. Since therewas no autopsy in themajority of cases, the
cause of death, whether it was cardiovascular or cancer related,
was not differentiated; therefore, mortality was deﬁned as
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all-cause mortality in this study. In the follow-up period, 97
patients died and/or 26 had thrombotic complication.
Laboratory Measurements
ADAMTS13 enzyme activity was determined in citrated
plasma samples using the ﬂuorogenic substrate FRETS-
VWF73 as previously described.24
VWF:Ag level was measured in EDTA plasma by ELISA as
described.25 Primary antibodies and horseradish peroxidise-
labeled polyclonal rabbit anti-human VWF antibodies were
used for the detection (both from Dako, Glostrup, Den-
mark).24 Determination of the additional laboratory para-
meters including complete blood counts, clinical chemistry
and tumour markers were completed by Roche Integra 800
analyser, and a Cell-Dyn 3500 haematology analyser.
VWF multimer analysis was performed with patients’
plasma samples which were normalized to VWF:Ag concen-
tration based on VWF:Ag ELISA results. VWF multimer gels
(1.2% (w/v) type VIIA agarose [Sigma-Aldrich] running gel and
SeaKem HGT(P) agarose [Lonza] stacking gel) were loaded
with denaturated normalized plasmas diluted in sample buf-
fer. Gels were run overnight and blotted into a nitrocellulose
membrane (Whatman Protran). Membranes were blocked in
1.5% milk shaking and probed with rabbit polyclonal antihu-
man VWF (DAKO) at 1:2.000, conjugatedwith goat anti-rabbit
HRPantibody (Biorad) anddevelopedusingchemiluminescent
substrate (Sigma-Aldrich). Digital images were acquired, den-
sitometry waveforms were generated using Alpha Innotech
(Fluorchem Ltd) and multimer structures of patients were
compared with normal pooled plasma (NPP). A sample was
deﬁned as positive for the presence of ultra-large von Wil-
lebrand factor (ULVWF) if bandswithmore than 15multimers
were present.
Statistical Analysis
The continuous variables reported in this study showed
skewed distribution according to the results of the Shapiro-
Wilk test deviated from the normal distribution. Therefore, for
descriptive purposes, the values of each measurement are
given as median and 25th to 75th percentile or as numbers
(percent) and non-parametric tests (Spearman’s rank correla-
tion or Mann–Whitney U-test) were used for group compar-
isons. For categorical variables, Pearson’s chi-square test was
applied. The correlation between the different variables was
determined by using Spearman’s correlation analysis.
MultivariableCoxproportionalhazardmodelswereﬁttedto
assess theeffectofplatelet count,VWF:Ag level andADAMTS13
activity on the event-free survival in patients. Survival times
were measured from the diagnosis of colorectal cancer and
patientswere censored at the time ofdeath, at the time of non-
fatal thromboembolic event, or at the end of the follow-up
period if still alive (month 60). Potential predictors of events
and confounders were entered into the models as categorical
variables, and high or low predictor groupswere formed based
on the results of receiver operating characteristic (ROC) curve
analysis. All of the survivalmodelswere adjusted to age, gender
and stage ofdisease. The proportional hazards assumptionwas
conﬁrmed graphically by Kaplan–Meier analysis, survival
curves were compared with log-rank (Mantel-Cox) test. The
results of the Cox regression models are presented as hazard
ratios (HRs)with corresponding 95% conﬁdence intervals (CIs).
With a sample size of 232 and a predicted event rate around
Table 1 Clinical and laboratory characteristics of patients with colorectal cancer
Patients who had an
event within 5 ya
Patient who
had no eventa
p-Valuec All patients
Number of patients 105 127 – 232
Males/Females 64/41 74/53 0.607 138/94
Age at diagnosis, y 70.3 (65–76.2)b 65.2 (58–72) <0.0001 68.5 (59.6–74.1)
Platelet G/L 309 (240–413) 271 (217–326) 0.013 286 (224.5–364.50)
ADAMTS activity, % 71.17 (59.33–88.45) 83.95 (70.71–104.66) <0.0001 78.40 (65.02–96.79)
VWF antigen, ng/mL 665.74 (369.75–1,433.4) 414.75 (254.37–764.54) 0.001 521.83 (286.10–1,067.97)
Carcinoembryonic
antigen, µg/L
4.45 (2–55) 1.8 (1–3.4) <0.0001 2.50 (1.20–7.40)
CA19–9, U/mL 11 (6.8–116.9) 7.75 (4.15–14.2) <0.0001 9.00 (5.0–20.30)
Body mass index 26.27 (24.2–29.74) 26.59 (24.54–29.4) 0.749 26.45 (24.22–29.40)
Stage
1 1 (1.0%) 8 (6.3%) <0.0001 9 (3.9%)
2 29 (27.6%) 72 (56.7%) 101 (43.5%)
3 32 (30.5%) 41 (32.3%) 73 (31.5%)
4 43 (41%) 6 (4.7%) 49 (21.1%)
Abbreviations: ADAMTS13, a disintegrin and metalloproteinase with thrombospondin type-I repeats 13; VWF, von Willebrand factor.
aNonfatal thromboembolic event and/or death of any cause.
bMedian and interquartile range or number and percentages.
cChi-square test or Mann–Whitney t-test.
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0.5, the precision of Cox regression models are considered
satisfactory, as reﬂected by the sufﬁciently narrow CI ranges.
The presence of collinearity in the multivariable models was
inferredbycalculating variance inﬂation factors (VIF). IBMSPSS
Statistics 20 and Graph Pad Prism 5 software were used for
the statistical analysis and presentation of data. Two-tailed
p-valueswere calculated and signiﬁcance level of p < 0.05was
used, if not otherwise stated.
Results
A total of 232 patients with colorectal cancer, with a mean age
of 68.5 years and slight male predominance (►Table 1), were
enrolled in the study and followed up for 5 years. Over the
5-year-long follow-up period, 96 patients died and/or 26 had a
thromboembolic event. Clinical and laboratory variables of the
cohort are summarized in►Table 1. Among these 26 patients,
there were 8 patients who had only thromboembolic compli-
cations but did not die within the follow-up period, whereas
2 patients had a fatal thromboembolic event, and 18 patients
died within the follow-up period after surviving thromboem-
bolic event. Accordingly, during follow-up, 105 patients suf-
fered nonfatal thromboembolic events, or died.
As presented in►Table 1, mortality and/or thromboembolic
events were associated with signiﬁcantly higher platelet count
(p ¼ 0.013), VWF:Ag level (p ¼ 0.001), carcinoembryonic anti-
gen- (CEA) and CA19–9 (cancer antigen 19–9) levels (all
p < 0.0001), and lower ADAMTS13 activity (p < 0.0001). Simi-
larly, advanced disease stage was also associated with poor
outcome (p < 0.0001). In 26 cases, thromboembolic complica-
tion occurred during the follow-up period. We found that
patients with thromboembolism had lower ADAMTS13 activity
(63.23%; 55.14–68.97%; p < 0.0001) and higher VWF:Ag
(665.74 ng/mL; 387.56–2,092.92 ng/mL; p ¼ 0.048) levels,
when compared with patients without events (ADAMTS13
activity: 80.27% [67.58–98.92%]; VWF:Ag level: 514.43 ng/mL
[280.73–964.27 ng/mL]), which also supports the hypothesis
that the observed decrease of ADAMTS13 activity in colorectal
cancer patients is clinically relevant. There was no correla-
tion between VWF:Ag levels, ADAMTS13 activity and platelet
count using Spearman’s correlation (ADAMTS13-VWF:Ag:
r ¼  0.114, p ¼ 0.08; ADAMTS13-platelet count: r ¼ 0.043,
p ¼ 0.526; VWF:Ag-platelet count: r ¼ 0.022, p ¼ 0.746).
IncreasedVWF:Ag levels anddecreasedADAMTS13activity
wereobserved formanyofourpatients. Therewere49patients
with high VWF:Ag level and low ADAMTS13 activity which is
21.6% of our patients (the other groups were as follows: low
ADAMTS13–low VWF:AG: n ¼ 16 [7%]; high ADAMTS13 ac-
tivity–lowVWF:Ag: n ¼ 46 [20.3%]; highADAMTS13 activity–
high VWF:AG: n ¼ 116 [51.1%]). Decreased ADAMTS13 activ-
ity with the presence of ultra-large VWF multimers was
observed in several diseases such as TTP, HUS, preeclampsia,
liver cirrhosis, chronic renal insufﬁciency and acute inﬂam-
matory states,26 and was found to be linked to higher risk of
thromboembolism.27 Therefore, by analysing the presence
of ultra-large VWF (ULVWF) oligomers in a selected subset
ofpatients (in55plasmasamplesobtained frompatients in the
highest VWF:Ag level group associated with the lowest
ADAMTS13 activity [n ¼ 28] or vice versa [n ¼ 27]), we
further examined if the observed increase of VWF:Ag with
the decrease of ADAMTS13 activity is clinically relevant or not.
Oligomeric structure of VWF was determined by agarose
electrophoresis, and a sample was considered positive for
ULVWF if VWF with more than 15 multimers was present
(►Fig. 1). A signiﬁcantly (p ¼ 0.01) increased frequency (67%)
of ULVWF was observed in the high VWF:Ag and low
ADAMTS13 activity group of colorectal cancer patients,
when compared with the low VWF:Ag and high ADAMTS13
activity group (32%,►Supplementary Table S1 [online only]),
indicating clinical relevance of this observation. Taken to-
gether, these data support that lower ADAMTS13 activity
and higher VWF:Ag level could be useful information accord-
ing to the prothrombotic state in the patients.
Next, we examined whether baseline platelet count, VWF-
antigen level and ADAMTS13 activity are associated with
disease stage (►Fig. 2). We merged stages 1 and 2 because
of the small number of cases. Signiﬁcantly higher platelet
counts (p ¼ 0.005), VWF:Ag levels (p ¼ 0.008) and decreased
ADAMTS13 activity (p ¼ 0.006)were observed in the group of
patients with metastatic disease (stage 4) when compared
with patients in stages 1 and 2 or when compared the patients
with lymph node metastasis (stage 3, all p < 0.05, except for
VWF:Ag where this difference was nonsigniﬁcant). We also
analysed the association between platelet counts, ADAMTS13
activity and VWF:Ag levels in the total cohort and no correla-
tion was observed between any of the markers.
To examine inmultivariablemodelswhether platelet count,
VWF:Ag level or ADAMTS13 activity could inﬂuence or have
any relation with event-free survival, patients were categor-
ized as those with “high” or “low” marker levels. The cut-off
values (indicated in ►Tables 2–4), with optimum sensitivity
and speciﬁcity for all-causemortality of the above-mentioned
variableswere deﬁned by ROC curve analysis. The distribution
of the clinical and laboratory characteristics of patients with
high or low platelet count, VWF:Ag level and ADAMTS13
activity is shown in ►Tables 2 to 4.
Fig. 1 Multimeric analysis of plasma von Willebrand factor (VWF). Oligo-
meric structure of VWF was determined by agarose electrophoresis, ULVWF
was deﬁned if bands representingmore than15-meroligomerswere present
in patients' plasma samples. Oligomeric structures of nine representative
samples are shown, samples 1 to 4 are negative, whereas samples 5 to 9 are
positive for ULVWF (marked by squares). Normal human plasma (NP) is
presented as negative control.
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In addition, we examined the levels of different tumour
markers in these groups (►Tables 2–4). Higher CA19–9 levels
were associatedwith elevated levels of VWF:Ag anddecreased
ADAMTS13 activity, whereas increased platelet count was
associated with higher CEA levels (►Table 2).
By examining the association between TNM classiﬁcation
and the above markers, we found that advanced stages were
signiﬁcantlyassociatedwithhighplateletcount (p ¼ 0.001)and
lower ADAMTS13 activity (p ¼ 0.011), and a borderline asso-
ciation (p ¼ 0.074) with high VWF:Ag level was also observed.
The cumulative event-free survival of patients with differ-
ent platelet counts, ADAMTS13 activity and VWF:Ag levels is
displayed in ►Fig. 3. Results of the Kaplan–Meier analysis
showed that lower platelet counts (p < 0.0001), lower
VWF:Ag (p ¼ 0.0008) levels, and higher ADAMTS13 activity
(p < 0.0001) were associated with better event-free survival.
Overall event-free survival at theendof follow-upwas61.68% in
the lowand38.57% in thehighplatelet count group, 32.8% in the
lowand64.02% in thehighADAMTS13 activity group and62.5%
in the low and 49% in the high VWF:Ag group.
Finally, to investigate the association between overall event-
free survival and the three studied variables, multivariate Cox
proportional hazardmodelswere generated, and the results are
shown in►Table 5. The baselinemodel (Model 1) included age,
gender and disease stage, and all subsequent models were
adjusted for these three variables. Next, platelet count,
ADAMTS13 activity and VWF:Ag level (as binary variables)
were incorporated (Models 2, 3 and 4) and all of these variables
Fig. 2 Box plot of the studied three variables according to different tumour stages. (Panel A) Platelet count; (Panel B) von Willebrand factor
antigen level; (Panel C): ADAMTS13 activity. The difference between stages 1, 2 and 4 is signiﬁcant (p < 0.05) in all panels. In Panels A and C,
there is a signiﬁcant difference between Stages 3 and 4 as well (both p < 0.05). Horizontal lines show medians. The boxes enclose interquartile
range and whiskers indicate the 5th to 95th percentiles of the groups.  p < 0.05.
Table 2 Clinical and laboratory characteristics of patients with high or low platelet count
Platelet count  348.5 G/Lb Platelet count > 348.5 G/L p-Valuec
Number of patients 154 70 –
No event/eventa 95/59 27/43 0.001
Males/Females 103/51 30/40 0.001
Age at diagnosis, y 68.35 (59.60–73.30) 68.70 (60.40–74.90) 0.407
ADAMTS13 activity, % 79.31 (65.04–98.69) 75.89 (65.8–94.18) 0.473
VWF antigen, ng/mL 501.28 (262.72–1,048.03) 576.60 (348.14- 1011.30) 0.405
Carcinoembryonic antigen, µg/L 2.00 (1.10–3.50) 5.80 (2.20–19.70) <0.0001
CA19–9, U/mL 9.10 (5.30–16.70) 8.30 (4.20–63.50) 0.754
Body mass index 27.17 (24.84–29.74) 26.11 (22.31–29.75) 0.111
Stage
1 9 (5.8%) 0 (0.0%) 0.001
2 73 (47.4%) 26 (37.1%)
3 50 (32.5%) 19 (27.1%)
4 22 (14.3%) 25 (35.7%)
Abbreviations: ADAMTS13, a disintegrin and metalloproteinase with thrombospondin type-I repeats 13; VWF, von Willebrand factor.
aNonfatal thromboembolic event and/or death of any cause.
bMedian and interquartile range or number and percentages.
cChi-square test or Mann–Whitney t-test.
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turnedout tobeage-, gender-andstage-independentpredictors
of mortality or thromboembolic complications (all HR >1.7,
p < 0.05, ►Supplementary Table S2 [online only]). When we
further adjusted Models 2 to 4 also for the well-known tumour
markers of colorectal cancer (CEA, CA19–9), which were asso-
ciated with mortality or thromboembolic complications
(►Table 1), all of the examined variables remained signiﬁcant
predictors of event-free state except ADAMTS13 activity (plate-
let count in Model 1 adjusted for CEA: HR 1.908, CI 1.214–3;
ADAMTS13activity inModel2adjusted forCA19–9:HR1.519,CI
0.955–2.416; VWF:Ag level inModel 3 adjusted for CA19–9: HR
2.021; CI 1.169–3.494). We also examined the relationship of
Table 3 Clinical and laboratory characteristics of patients with high or low ADAMTS13 activity
ADAMTS13 activity  66.53%b ADAMTS13 activity > 66.53% p-Valuec
Number of patients 67 164 –
No event/eventa 22/45 105/59 <0.0001
Males/Females 47/20 90/74 0.032
Age at diagnosis, y 72.40 (67.80–78.60) 65.45 (58.10–71.80) <0.0001
Platelet G/L 266 (214–353) 291 (229–367) 0.343
VWF antigen, ng/mL 635.40(318.0–1,286.51) 502.62 (280.73–904.66) 0.207
Carcinoembryonic antigen, µg/L 3.20 (1.10–28.90) 2.30 (1.20–5.20) 0.090
CA19–9, U/mL 12.40 (7.10–49.40) 8.10 (4.50–16.70) 0.008
Body mass index 26.11 (24.78–29.08) 27.04 (23.67–29.40) 0.734
Stage
1 2 (3.0%) 7 (4.3%) 0.011
2 20 (29.9%) 81 (49.4%)
3 23 (34.3%) 50 (30.5%)
4 22 (32.8%) 26 (15.9%)
Abbreviations: ADAMTS13, a disintegrin and metalloproteinase with thrombospondin type-I repeats 13; VWF, von Willebrand factor.
aNonfatal thromboembolic event and/or death of any cause.
bMedian and interquartile range or number and percentages.
cChi-square test or Mann–Whitney t-test.
Table 4 Clinical and laboratory characteristics of patients with high or low von Willebrand factor antigen
von Willebrand factor
antigen  305.6 ng/mLb
von Willebrand factor
antigen > 305.6 ng/mL
p-Valuec
Number of patients 62 165 –
No event/eventa 45/17 81/84 0.002
Males/Females 40/22 94/71 0.303
Age at diagnosis, y 65.55 (58.50–73.00) 68.80 (60.60–74.70) 0.067
Platelet G/L 282 (223–339.5) 291 (227–368) 0.298
ADAMTS13 activity, % 83.88 (66.42–98.45) 77.74 (65.02–95.12) 0.377
Carcinoembryonic antigen, µg/L 2.15 (1.10–4.20) 2.70 (1.20–8.50) 0.134
CA19–9, U/mL 7.45 (4.20–14.20) 9.50 (5.60–21.90) 0.03
Body mass index 26.20 (22.59–28.23) 26.93 (24.39–29.76) 0.164
Stage
1 2 (3.2%) 7 (4.2%) 0.074
2 33 (53.2%) 67 (40.6%)
3 21 (33.9% 50 (30.3%)
4 6 (9.7%) 41 (24.8%)
Abbreviation: ADAMTS13, a disintegrin and metalloproteinase with thrombospondin type-I repeats 13.
aNonfatal thromboembolic event and/or death of any cause.
bMedian and interquartile range or number and percentages.
cChi-square test or Mann–Whitney t-test.
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these variables for an aggregate effect on event-free survival
(Model5,►Table 5) andobserved that plateletcount (HR:1.967,
CI:1.257–3.077),ADAMTS13activity (HR:1.903,CI:1.22–3.577)
and VWF:Ag level (HR: 2.089, CI: 1.169–3.651) remained sig-
niﬁcant predictors of mortality or thromboembolic complica-
tions in the ﬁnal multivariable model. Multiple collinearity was
not present in theﬁnal multivariable model, since all VIF scores
were in the range 1 to 10.
Based on all of the above observations, careful analysis
and interpretation of platelet count, ADAMTS13 activity and
VWF:Ag level may yield clinically important information
in colorectal cancer, since these markers are associated
with increased prothrombotic risk and independently pre-
dict worse outcome.
Discussion
In this cohort study with a 5-year follow-up, we report that
platelet count, ADAMTS13 activity and VWF:Ag levels are
related to different stages of colorectal cancer and have prog-
nostic signiﬁcance. Higher platelet count, VWF:Ag level and
lower ADAMTS13 activity are associated with advanced stage
and independently and signiﬁcantly predicts poor overall
event-free survival. The novelty of this study is the demonstra-
tionofa clinically relevantdecreaseofADAMTS13activitywith
increased thromboembolic risk in colorectal cancer, and the
independent association of higher platelet count, higher VWF:
Ag levels and lowerADAMTS13activitywithpoor thromboem-
bolic event-free survival in colorectal cancer patients. Higher
occurrence of ultra-large VWF oligomers in colorectal cancer
patients with increased VWF:Ag and decreased ADAMTS13
activity strongly supported clinical relevance of this observa-
tion. Taken together, previous literature results20,21 and our
observations in colorectal cancer patients are convincingly
supporting the link between increased VWF:Ag, decreased
ADAMTS13 activity and increased prothrombotic risk.
Fig. 3 Kaplan–Meier analysis of patient groups with higher and lower
levels of the studied variables. (Panel A) Platelet count, thick line:
>348.5 G/L, thin line: 348.5 G/L; (Panel B): von Willebrand factor
antigen level, thick line: >305.6 ng/mL, thin line: 305.6 ng/mL;
(Panel C): ADAMTS13 activity, thick curve:  66.53%, thin curve:
>66.53%. p-Value of log-rank test is indicated.
Table 5 Model5:Relationshipbetweenplatelet count,ADAMTS13
activity andvonWillebrand factor antigenandevent-free survival of
232patientswithcolorectal cancerduring the5-year-long follow-up
period
HR CI p-Value
Age
(by 10 y of increase)
1.277 1.034–1.576 0.023
Gender
Female
Male
1
0.876
0.562–1.366 0.559
Stage
1, 2, 3
4
1
3.638
2.345–5.645 <0.0001
Platelet count
 348.5 G/L
> 348.5 G/L
1
1.967
1.257–3.077 0.003
ADAMTS13 activity
> 66.53%
 66.53%
1
1.903
1.22–3.577 0.003
von Willebrand factor antigen
 305.6 ng/mL
> 305.6 ng/mL
1
2.089
1.169–3.651 0.007
Abbreviation: ADAMTS13, a disintegrin and metalloproteinase with
thrombospondin type-I repeats 13.
Note: The effect of different other demographic and clinical variables
was calculated by multivariable Cox regression analysis.
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An important observation of the current study is the de-
monstration of association between thrombocytosis with poor
5-year event-free survival in colorectal cancer, conﬁrming
previous results.6–13,15 Elevated platelet count was associated
with metastatic (stage 4) disease, whereas patients with loco-
regionaldisease (stage3)had similar platelet counts aspatients
with stage 1 to 2 diseases (►Fig. 1). The association between
metastatic disease and thrombocytosis is intriguing. During
metastasis formation, cancer cells escape from the primary
tumourandget todistal siteswhile thecells arehiddenfromthe
tumour surveillancemechanisms.28 There is growing evidence
of an interaction between tumour cells and platelets which
may promote tumour cell survival and tumour progression.
The surface receptors of platelets (adhesion receptors such as
GP IIb/IIIa, GP Ib-IX-V and integrins αvβ3) can directly interact
with tumour cells leading to the formation of heteroaggre-
gates.5 The interaction of platelets with tumour cells may also
lead to platelet activation, aggregation5 and degranulation,28
a process called tumour cell-induced platelet aggregation
(TCIPA).4,28 Factors released from the α-granules include
PDGF, VEGF, IGF-1 and TGFβ, which may contribute to tumour
growth, spread and neovascularization.
Both the thrombin- and the VEGF-dependent pathways
induce endothelial cell activation followed by Weibel-Palade
body exocytosis and the release of VWF.29 Von Willebrand
factor is a key regulator of primary haemostasis,16 as the
released multimer can bind to platelet surface receptors and
promote the formation of the platelet thrombus.17,30 Recent
observations obtained from human clinical samples support a
VWF-mediated mechanism in tumour progression and angio-
genesis, where tumour-derived VEGF plays a pivotal role.
Analysis of human blood samples and tumour tissue revealed
that VWF release combined with a local inhibition of proteo-
lytic activity and protein expression of ADAMTS13 accounted
for a tumour propagating procoagulatory milieu.31 Increased
plasma levels of VWF:Ag were associatedwith poor prognosis
in different types of cancer (ovarian, bladder, gastric and
colon).16,17,32,33 Increased expression of VWF was observed
in the tumour compared with the non-tumoural parenchyma
in gastric cancer, and late gastric cancer showed signiﬁcantly
higher levels of VWF:Ag.16 The GPIbα receptor can be ex-
pressed by various tumour cells, such as human breast cancer
cells, and it was suggested that the function of this receptor on
tumour cells differs in its adhesive interaction with VWF from
that of platelets.34,35 The most active, ultra-large form of VWF
is released from the endothelial Weibel-Palade bodies,36 and
ADAMTS13-mediated proteolytic processesmay be decreased.
Hence, the cumulative action of these processes may lead to
the formation of ﬁrm tumour–platelet aggregates linked
by ﬁbres of ultra-large VWF.31 Our observations are in line
with this mechanism, since we were able to show in this
study the independent association of decreased ADAMTS13
activity (72.28% on average) and increased VWF:Ag levels
(677.86 ng/mL on average) with poor event-free survival
of patients with colorectal cancer. The analysis of the oligo-
meric form of VWF showed that ultra-large oligomers
occurred more frequently in patients with high VWF:Ag
levels and low ADAMTS13 activity, when compared with
those with low VWF:Ag levels and high ADAMTS13 activity
group (►Supplementary Table S1 [online only]). Decreased
ADAMTS13 activity with increased VWF:Ag levels was asso-
ciated with increased occurrence of thromboembolic events
which support the clinical relevance of this observation
(►Supplementary Table S1 [online only]). Decreased activity
of ADAMTS13was observed in clinical studies in the plasma of
patients with different malignancies mostly in advanced,
disseminated stages;19,22 however, this is the ﬁrst study
providing epidemiologic evidence for the association between
decreasedADAMTS13 activityandpoor event-free survival in a
5-year-long follow-up study. Our current observations are in
line with results of previous studies and may support the
important role of ADAMTS13 and VWF in the pathomechan-
ism of cancer-related thromboembolism and mortality.
In summary, this is the ﬁrst observational study reporting
platelet count, ADAMTS13 activity and VWF:Ag level simulta-
neously in colorectal cancer. We showed that thrombocytosis,
elevated VWF:Ag levels and decreased VWF-processing pro-
tease activity independently associate with poor event-free
survival. Therefore, these epidemiological data may support
priorobservationsobtained fromanimalclinical studieson the
contribution of tumour cell–platelet heteroaggregates, held
together by VWF-ﬁbres, in the propagation of tumour pro-
gression. These observations may therefore provide further
support to plan novel therapies targeting endothelial cell
activation or microthrombi formation in cancer treatment.
What is known about this topic?
• Metastasis formation is the leading cause of cancer-
relateddeath.There isgrowingevidenceofaninteraction
between tumourcells andplateletswhichmay inﬂuence
tumour progression and metastasis formation and may
be regulated by the VWF.
• Preoperative thrombocytosis and increased VWF:Ag
level are associated with poor prognosis in different
types ofcancer. In disseminatedmalignancies, decreased
ADAMTS13 serum levels were measured.
• It is important to ﬁnd new reliable markers which can
predict prognosis in colorectal cancer.
What does this paper add?
• We measured ADAMTS13 activity in a large cohort of
colorectal cancer patients at the ﬁrst time and ob-
served the association of decreased activity—together
with increased platelet count and VWF:Ag level—with
poor survival without thrombotic complications.
• Wereport that increasedplatelet count,VWF:Ag level and
decreasedADAMTS13 activity are all independently asso-
ciatedwithadvancedstageandpoorerevent-freesurvival.
• These observational data may fuel further research on
tumour cell–platelet heteroaggregates, to explore the role
of VWF-ﬁbres in tumour progression and metastasis for-
mation andmay ﬁnally highlight novel targets of therapy.
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